Menu Search
Equities

Nanobiotix SA

5NR:FRA

Nanobiotix SA

Actions
  • Price (EUR)3.84
  • Today's Change0.06 / 1.59%
  • Shares traded1.00k
  • 1 Year change-29.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Nanobiotix SA grew revenues -- from 0.00 to 30.06m while net income improved from a loss of 57.04m to a smaller loss of 39.70m.
Gross margin--
Net profit margin-92.42%
Operating margin-63.12%
Return on assets-52.68%
Return on equity--
Return on investment-323.15%
More ▼

Cash flow in EURView more

In 2023, Nanobiotix SA increased its cash reserves by 81.90%, or 33.90m. Cash Flow from Financing totalled 46.77m or 155.60% of revenues. In addition the company used 12.48m for operations while cash used for investing totalled 349.00k.
Cash flow per share-0.7425
Price/Cash flow per share--
Book value per share-0.4594
Tangible book value per share-0.4596
More ▼

Balance sheet in EURView more

Nanobiotix SA has a Debt to Total Capital ratio of 186.52%.
Current ratio1.42
Quick ratio--
Total debt/total equity--
Total debt/total capital1.87
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.